Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CRNX stock hub

Crinetics Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CRNXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CRNX

In the news

Latest news · CRNX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-39.2

P25 -105.6P50 -46.5P75 -3.1

ROIC-25.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CRNX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001658247
Company name	Crinetics Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	22663K107
Employees	594
Employees Change	157%
Employees Change Percent	35.93
Enterprise value	$2.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-07-18
Isin	US22663K1079
Last refreshed	2026-05-10
Market cap	$4B
Market cap category	Mid-Cap
Price	$37.48
Price currency	USD
Rev Per Employee	30,419.19x
Sector	Healthcare
Sic	2834
Symbol	CRNX
Website	https://www.crinetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.56%
EV Sales Forward	31.83x
EV/Sales	149.89x
FCF yield	-10.62%
P/B ratio	3.08x
P/S ratio	218.71x
PS Forward	46.44x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-315.3M
Net Income	$-496.4M
Net Income Growth Years	0%
Pretax Margin	-2,746.18%
Profit Per Employee	$-835,670
ROA	-24.69
Roa5y	-25.78
ROCE	-41.03
ROE	-39.17
Roe5y	-43.18
ROIC	-25.91

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	19.42%
Cagr3y	18.8%
Cagr5y	17.19%
EPS Growth Years	0
Revenue Growth	2,277.5x
Revenue Growth Q	2,873.41x
Revenue Growth Quarters	1x
Revenue Growth Years	1x
Revenue Growth3 Y	61.56x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$1.4B
Cash	$1.3B
Current Assets	$1.3B
Current Liabilities	$71.1M
Debt	$47.9M
Debt Equity	$0.04
Equity	$1.3B
Liabilities	$120.7M
Long Term Assets	$78.9M
Long Term Liabilities	$49.6M
Net Cash	$1.2B
Net Cash By Market Cap	$31.46
Net Cash Growth	1.65%
Net Debt Equity	$-0.97
Tangible Book Value	$1.3B
Tangible Book Value Per Share	$12.16
WACC	5.74

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	18.6
Net Working Capital	$-33.4M
Quick ratio	18.25
Working Capital	$1.3B
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-12.58%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	19.4%
200-day SMA	40.92
3Y total return	67.7%
50-day SMA	38.27
50-day SMA vs 200-day SMA	50under200
5Y total return	120.99%
All Time High	62.53
All Time High Change	-40.06%
All Time High Date	2024-11-14
All Time Low	10.63
All Time Low Change	252.59%
All Time Low Date	2020-03-17
ATR	2.19
Beta	0.28
Beta1y	1.02
Beta2y	1.53
Ch YTD	-19.48
High	43.31
High52	57.99
High52 Date	2026-01-05
High52ch	-35.37%
Low	36.73
Low52	25.83
Low52 Date	2025-08-08
Low52ch	45.1%
Ma50ch	-2.07%
Premarket Change Percent	-0.67
Premarket Price	$43.2
Premarket Volume	16,964
Price vs 200-day SMA	-8.41%
RSI	43.76
RSI Monthly	48.66
RSI Weekly	44.25
Sharpe ratio	0.52x
Sortino ratio	0.98
Total Return	-12.58%
Tr YTD	-19.48
Tr1m	-2.42%
Tr1w	-3.95%
Tr3m	-17.23%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	6
Analyst Price Target Top	$80.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.23
Earnings Revenue Estimate	8,323,400x
Earnings Revenue Estimate Growth	2,205.65x
Operating Income	$-545.7M
Operating margin	-3,020.3
Price target	$76.5
Price Target Change	$104
Price Target Change Top	$115

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	96,988,790%
Float Percent	91.98%
Shares Insiders	1.44%
Shares Institutions	101.86%
Shares Out	105,440,208
Shares Qo Q	9.47%
Shares Yo Y	12.58%
Short Float	13.19%
Short Ratio	10.59
Short Shares	12.14

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-519.7M
Average Volume	1,300,580.4x
Bv Per Share	12.16
CAPEX	$-5.3M
Ch1m	-2.42
Ch1w	-3.95
Ch1y	19.4
Ch3m	-17.23
Ch3y	67.7
Ch5y	121
Ch6m	-6.3
Change	-13.82%
Change From Open	-12.98
Close	43.49
Days Gap	-0.97
Depreciation Amortization	4,125,000
Dollar Volume	180,463,726.3
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-545.7M
EBITDA	$-541.6M
EPS	$-5.13
F Score	3
FCF	$-419.5M
FCF EV Yield	-15.49x
FCF Per Share	$-3.98
Financing CF	426,049,000
Fiscal Year End	December
Founded	2,008
Income Tax	$180,000
Investing CF	7,510,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	43.67
Ma150ch	-14.18%
Ma20	39.55
Ma20ch	-5.23%
Net CF	19,272,000
Next Earnings Date	2026-08-06
Open	43.07
Optionable	Yes
Position In Range	11.4
Post Close	37.48
Postmarket Change Percent	-0.07
Postmarket Price	$37.46
Ppne	53,287,000
Pre Close	43.49
Price Date	2026-05-08
Ptbv Ratio	3.09
Relative Volume	3.7x
Revenue	18,069,000x
SBC By Revenue	554.68x
Share Based Comp	100,226,000
Tax By Revenue	1x
Tr6m	-6.3%
Us State	California
Volume	4,814,934

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CRNX pay a dividend?

Capital-return profile for this ticker.

Performance

CRNX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CRNX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+101.9%

Float: +92.0% of shares outstanding

Insider ownership

+1.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CRNX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.8

Neutral momentum band

Price vs 200-day MA

-8.4%

50/200-day relationship not available

Beta (5Y)

0.28

Less volatile than the market

Sharpe ratio

0.52

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CRNX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CRNX stock rating?

Crinetics Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CRNX analysis?

The full report lives at /stocks/CRNX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CRNX?

The latest report frames CRNX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CRNX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.